Abstract
Background: Previous studies have suggested that niacin may have antiplatelet properties, however the effects of niacin on the platelet activity are not well defined.
Objective: The purpose of this trial was to investigate whether the oral administration of niacin inhibits platelet aggregation.
Method: This study was run in three segments measuring the inhibitory effect of niacin: 1) 3 mmol/L niacin in vitro, 2) one hour after 1-gram sustained-release (SR) niacin administration, 3) twelve hours after 2-gram SR niacin administration. Platelet aggregation was measured using the VerifyNow-Aspirin and whole blood impedance aggregometry.
Results: Preincubation with niacin resulted in a significant inhibition of platelet aggregation. Significant inhibition of platelet aggregation was found one hour following the oral administration of 1 gram of SR niacin while the oral administration of a 2 gram dose of SR niacin did not produce significant platelet inhibition when platelet aggregation was measured 12 hours after the dose.
Conclusion: Niacin has a small, direct effect on platelet aggregation. Niacin platelet inhibition is transient and may dissipate as it is converted into metabolites. The clinical significance is unknown.
Keywords: Niacin, pharmacology, pharmacodynamics, platelet aggregation.
Current Clinical Pharmacology
Title:Oral Administration of Sustained Release Niacin Inhibits Platelet Aggregation
Volume: 11 Issue: 1
Author(s): Nicholas B. Norgard, Nicholas R. Bacon and Matthew Agosti
Affiliation:
Keywords: Niacin, pharmacology, pharmacodynamics, platelet aggregation.
Abstract: Background: Previous studies have suggested that niacin may have antiplatelet properties, however the effects of niacin on the platelet activity are not well defined.
Objective: The purpose of this trial was to investigate whether the oral administration of niacin inhibits platelet aggregation.
Method: This study was run in three segments measuring the inhibitory effect of niacin: 1) 3 mmol/L niacin in vitro, 2) one hour after 1-gram sustained-release (SR) niacin administration, 3) twelve hours after 2-gram SR niacin administration. Platelet aggregation was measured using the VerifyNow-Aspirin and whole blood impedance aggregometry.
Results: Preincubation with niacin resulted in a significant inhibition of platelet aggregation. Significant inhibition of platelet aggregation was found one hour following the oral administration of 1 gram of SR niacin while the oral administration of a 2 gram dose of SR niacin did not produce significant platelet inhibition when platelet aggregation was measured 12 hours after the dose.
Conclusion: Niacin has a small, direct effect on platelet aggregation. Niacin platelet inhibition is transient and may dissipate as it is converted into metabolites. The clinical significance is unknown.
Export Options
About this article
Cite this article as:
Norgard B. Nicholas, Bacon R. Nicholas and Agosti Matthew, Oral Administration of Sustained Release Niacin Inhibits Platelet Aggregation, Current Clinical Pharmacology 2016; 11 (1) . https://dx.doi.org/10.2174/1574884711666151214104315
DOI https://dx.doi.org/10.2174/1574884711666151214104315 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Utilization of Microfluidics for the Preparation of Polymeric Nanoparticles for the Antioxidant Rutin: A Comparison with Bulk Production
Pharmaceutical Nanotechnology Glycoxidation of Low Density Lipoprotein in Impaired Glucose Tolerance: Implications for the Pathogenesis of Diabetic Vascular Disease
Vascular Disease Prevention (Discontinued) Clinical Thiazolidinediones as PPARγ Ligands with the Potential for the Prevention of Cardiovascular Disease in Diabetes
Current Diabetes Reviews Vascular C-Reactive Protein in the Pathogenesis of Coronary Artery Disease:Role of Vascular Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets Risk Stratification of Dyslipidemia: Insights from the Framingham Study
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Fibrinolytic Factors in Liver Fibrosis
Current Pharmaceutical Biotechnology QSAR Studies on some Calcium Channel Blockers
Letters in Drug Design & Discovery Vascular Effects of Ambient Pollutant Particles and Metals
Current Vascular Pharmacology Fast Food Versus Slow Food and Hypertension Control
Current Hypertension Reviews Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Pleiotropic Beneficial Effects of Epigallocatechin Gallate, Quercetin and Delphinidin on Cardiovascular Diseases Associated with Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry Non-Lipid Effects of Statins: Emerging New Indications
Current Vascular Pharmacology Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Cleavage of Human Apolipoprotein(a) Coated on the Surface of Consituents of the Vascular Extracellular Matrix by Pancreatic Elastase and Metalloproteinase-12. Different Partitions Between Cleaved NTerminal and C-Terminal Domains
Vascular Disease Prevention (Discontinued) Metabolic Activation of Herbal and Dietary Constituents and Its Clinical and Toxicological Implications: An Update
Current Drug Metabolism Editorial (Hot Topic: Modifying Cardiovascular Risk Factors: New Markers of Cardiovascular Damage)
Current Pharmaceutical Design Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics